Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
J Antimicrob Chemother
; 61(6): 1359-61, 2008 Jun.
Article
em En
| MEDLINE
| ID: mdl-18343802
ABSTRACT
OBJECTIVES:
Data are scarce on the long-term efficacy of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented. PATIENTS ANDMETHODS:
Twenty-one HIV-infected patients with suppressed HIV replication (<50 copies/mL) for at least 6 months and without previous failure while receiving a protease inhibitor-based regimen started lopinavir/ritonavir monotherapy. Follow-up was performed within the OK pilot clinical trial during the first 2 years and according to routine clinical practice during the 3rd and 4th years.RESULTS:
Fourteen patients (67%) remain on monotherapy and with RNA <50 copies/mL (intention-to-treat analysis, with missing patients scored as failures). Five patients (24%) had virological rebound and all of them were successfully re-suppressed by adding two nucleosides. No major protease inhibitor mutations were found.CONCLUSIONS:
Our data support the long-term efficacy and safety of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression, a finding that must be confirmed in larger studies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirimidinonas
/
Infecções por HIV
/
Inibidores da Protease de HIV
/
Ritonavir
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article